首页 > 最新文献

Annals of surgery最新文献

英文 中文
Percent Thrombus Predicts Popliteal Artery Aneurysm Related Limb Threatening Events. 血栓百分比可预测腘动脉瘤相关的肢体威胁事件。
IF 6.4 1区 医学 Q1 SURGERY Pub Date : 2025-12-01 Epub Date: 2024-05-21 DOI: 10.1097/SLA.0000000000006352
Tiffany R Bellomo, Guillaume Goudot, Srihari K Lella, Brandon Gaston, Natalie Sumetsky, Shiv Patel, Nikolaos Zacharias, Anahita Dua

Objective: The objective of this study was to identify clinical and anatomic characteristics of Popliteal artery aneurysms (PAAs) associated with acutely limb-threatening events.

Background: Popliteal artery aneurysms (PAAs) are associated with high morbidity and mortality. Current guidelines recommend operative repair for PAAs with a diameter greater than 20 mm based on very limited evidence.

Methods: This retrospective cross-sectional cohort was derived from a multi-institutional database queried for all patients with a PAA from 2008 to 2022. Duplex ultrasound characteristics of PAAs were abstracted by registered physicians in vascular interpretation. Symptom status at the time of duplex ultrasound was divided into 3 categories: asymptomatic PAA, symptomatic PAA with claudication or chronic limb ischemia, and acutely limb-threatening PAAs with a thromboembolic event, acute limb ischemia, or rupture.

Results: There were 470 PAAs identified in 331 patients. The mean age was 74 years at diagnosis; 94% of patients were white, and 97% of patients were male. In a univariate analysis, patient comorbidities and medications were not associated with symptom status. In a multivariate analysis including age, a higher percent thrombus was significantly associated with symptomatic PAAs (RRR 15.2; CI: 2.69-72.3; P<0.01) and PAAs with an acutely limb-threatening event (RRR 17.9; CI: 3.76-85.0; P<0.01). All other anatomic characteristics were not associated with symptom status.

Conclusions: Percent thrombus was significantly associated with symptomatic PAAs and acutely limb-threatening events, whereas diameter was not significantly associated with any symptom group. This analysis supports the use of percent thrombus in identifying high-risk PAAs that warrant repair.

目的:本研究的目的是确定与急性肢体威胁事件相关的腘动脉瘤(PAA)的临床和解剖特征:本研究旨在确定与急性肢体威胁事件相关的腘动脉瘤(PAA)的临床和解剖特征:腘动脉瘤(PAA)与高发病率和高死亡率有关。基于非常有限的证据,现行指南建议对直径大于 20 毫米的腘动脉瘤进行手术修复:该回顾性横断面队列来自一个多机构数据库,该数据库查询了 2008 年至 2022 年期间所有 PAA 患者的资料。PAA的双相超声(DUS)特征由血管解读方面的注册医师摘录。DUS检查时的症状状态分为三类:无症状PAA、伴有跛行或慢性肢体缺血的有症状PAA,以及伴有血栓栓塞事件、急性肢体缺血或破裂的急性肢体威胁PAA:结果:在 331 名患者中发现了 470 个 PAA。诊断时的平均年龄为 74 岁,94% 的患者为白人,97% 的患者为男性。在单变量分析中,患者的合并症和药物与症状状态无关。在包括年龄在内的多变量分析中,较高的血栓百分比与有症状的 PAAs 显著相关(RRR 15.2;CI 2.69-72.3;PConclusion:血栓百分比与无症状 PAA 和急性肢体威胁事件明显相关,而直径与任何症状组别均无明显相关。这项分析支持使用血栓百分比来识别需要进行修复的高风险 PAA。
{"title":"Percent Thrombus Predicts Popliteal Artery Aneurysm Related Limb Threatening Events.","authors":"Tiffany R Bellomo, Guillaume Goudot, Srihari K Lella, Brandon Gaston, Natalie Sumetsky, Shiv Patel, Nikolaos Zacharias, Anahita Dua","doi":"10.1097/SLA.0000000000006352","DOIUrl":"10.1097/SLA.0000000000006352","url":null,"abstract":"<p><strong>Objective: </strong>The objective of this study was to identify clinical and anatomic characteristics of Popliteal artery aneurysms (PAAs) associated with acutely limb-threatening events.</p><p><strong>Background: </strong>Popliteal artery aneurysms (PAAs) are associated with high morbidity and mortality. Current guidelines recommend operative repair for PAAs with a diameter greater than 20 mm based on very limited evidence.</p><p><strong>Methods: </strong>This retrospective cross-sectional cohort was derived from a multi-institutional database queried for all patients with a PAA from 2008 to 2022. Duplex ultrasound characteristics of PAAs were abstracted by registered physicians in vascular interpretation. Symptom status at the time of duplex ultrasound was divided into 3 categories: asymptomatic PAA, symptomatic PAA with claudication or chronic limb ischemia, and acutely limb-threatening PAAs with a thromboembolic event, acute limb ischemia, or rupture.</p><p><strong>Results: </strong>There were 470 PAAs identified in 331 patients. The mean age was 74 years at diagnosis; 94% of patients were white, and 97% of patients were male. In a univariate analysis, patient comorbidities and medications were not associated with symptom status. In a multivariate analysis including age, a higher percent thrombus was significantly associated with symptomatic PAAs (RRR 15.2; CI: 2.69-72.3; P<0.01) and PAAs with an acutely limb-threatening event (RRR 17.9; CI: 3.76-85.0; P<0.01). All other anatomic characteristics were not associated with symptom status.</p><p><strong>Conclusions: </strong>Percent thrombus was significantly associated with symptomatic PAAs and acutely limb-threatening events, whereas diameter was not significantly associated with any symptom group. This analysis supports the use of percent thrombus in identifying high-risk PAAs that warrant repair.</p>","PeriodicalId":8017,"journal":{"name":"Annals of surgery","volume":" ","pages":"1134-1139"},"PeriodicalIF":6.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141074837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association Between Prescription Drug Monitoring Program Use Mandate and Opioid Prescribing and Patient-reported Outcomes After Surgery. 处方药监控计划使用授权与阿片类药物处方及术后患者报告结果之间的关联。
IF 6.4 1区 医学 Q1 SURGERY Pub Date : 2025-12-01 Epub Date: 2024-05-08 DOI: 10.1097/SLA.0000000000006332
Kao-Ping Chua, Thuy D Nguyen, Chad M Brummett, Amy S Bohnert, Vidhya Gunaseelan, Michael J Englesbe, Stephanie Lee, Jennifer F Waljee

Objective: To evaluate changes in opioid prescribing and patient-reported outcomes after surgery following the implementation of Michigan's prescription drug monitoring program (PDMP) use mandate in June 2018.

Background: Most states mandate clinicians to query PDMP databases before prescribing controlled substances. Whether these PDMP use mandates affect opioid prescribing and patient-reported outcomes after surgery is unclear, especially among patients with elevated "Narx" scores, a risk score for overdose death used in most PDMPs.

Methods: We conducted an interrupted time series analysis of a statewide surgical registry linked to Michigan's PDMP database. Analyses included adults undergoing general surgical procedures from January 2017 to October 2019. Outcomes included monthly mean days supplied in dispensed opioid prescriptions (those filled within 3 days of discharge) and monthly mean scores for 3 patient-reported outcomes (pain in the week after surgery, care satisfaction, and regret undergoing surgery). Segmented regression models were used to assess for level and slope changes in outcomes in June 2018. Analyses were repeated among patients with Narx scores ≥200, a threshold that defines the top quartile.

Results: The analyses included 21,897 patients. The mandate was associated with a -0.5 (95% CI: -0.8, -0.2) level decrease in mean days supplied in dispensed opioid prescriptions, but not with worsened patient-reported outcomes. Findings were similar among patients with Narx scores ≥200.

Conclusions: Following the implementation of Michigan's PDMP use mandate, the duration of opioid prescriptions decreased, but patient-reported outcomes did not worsen. The findings suggest that PDMP use mandates may not be associated with worsened experience among general surgical patients.

目的:评估 2018 年 6 月密歇根州实施处方药监控计划(PDMP)使用授权后,阿片类药物处方和患者报告的术后结果的变化:评估密歇根州于 2018 年 6 月实施处方药监控计划(PDMP)使用授权后,阿片类药物处方和患者报告的术后结果的变化:大多数州规定临床医生在开具受管制药物处方前必须查询处方药监控计划(PDMP)数据库。这些 PDMP 使用规定是否会影响阿片类药物处方和患者报告的术后结果尚不清楚,尤其是在 "Narx "评分升高的患者中,这是大多数 PDMP 中使用的过量死亡风险评分:我们对与密歇根州 PDMP 数据库相连的全州手术登记册进行了间断时间序列分析。分析对象包括 2017 年 1 月至 2019 年 10 月期间接受普通外科手术的成年人。分析结果包括每月平均阿片类药物处方供应天数(出院后 3 天内开具的处方)和 3 项患者报告结果(术后一周内的疼痛、护理满意度、对手术的遗憾)的每月平均得分。使用分段回归模型评估了 2018 年 6 月结果的水平和斜率变化。在Narx评分≥200分的患者中重复进行分析,该阈值定义了最高四分位数:分析包括 21,897 名患者。该规定与阿片类药物处方平均供应天数的-0.5(95% CI:-0.8,-0.2)级下降有关,但与患者报告的结果恶化无关。Narx评分≥200分的患者的研究结果与此类似:结论:密歇根州实施 PDMP 使用授权后,阿片类药物处方的持续时间缩短,但患者报告的结果并未恶化。研究结果表明,强制使用 PDMP 可能不会导致普通外科患者的治疗效果恶化。
{"title":"Association Between Prescription Drug Monitoring Program Use Mandate and Opioid Prescribing and Patient-reported Outcomes After Surgery.","authors":"Kao-Ping Chua, Thuy D Nguyen, Chad M Brummett, Amy S Bohnert, Vidhya Gunaseelan, Michael J Englesbe, Stephanie Lee, Jennifer F Waljee","doi":"10.1097/SLA.0000000000006332","DOIUrl":"10.1097/SLA.0000000000006332","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate changes in opioid prescribing and patient-reported outcomes after surgery following the implementation of Michigan's prescription drug monitoring program (PDMP) use mandate in June 2018.</p><p><strong>Background: </strong>Most states mandate clinicians to query PDMP databases before prescribing controlled substances. Whether these PDMP use mandates affect opioid prescribing and patient-reported outcomes after surgery is unclear, especially among patients with elevated \"Narx\" scores, a risk score for overdose death used in most PDMPs.</p><p><strong>Methods: </strong>We conducted an interrupted time series analysis of a statewide surgical registry linked to Michigan's PDMP database. Analyses included adults undergoing general surgical procedures from January 2017 to October 2019. Outcomes included monthly mean days supplied in dispensed opioid prescriptions (those filled within 3 days of discharge) and monthly mean scores for 3 patient-reported outcomes (pain in the week after surgery, care satisfaction, and regret undergoing surgery). Segmented regression models were used to assess for level and slope changes in outcomes in June 2018. Analyses were repeated among patients with Narx scores ≥200, a threshold that defines the top quartile.</p><p><strong>Results: </strong>The analyses included 21,897 patients. The mandate was associated with a -0.5 (95% CI: -0.8, -0.2) level decrease in mean days supplied in dispensed opioid prescriptions, but not with worsened patient-reported outcomes. Findings were similar among patients with Narx scores ≥200.</p><p><strong>Conclusions: </strong>Following the implementation of Michigan's PDMP use mandate, the duration of opioid prescriptions decreased, but patient-reported outcomes did not worsen. The findings suggest that PDMP use mandates may not be associated with worsened experience among general surgical patients.</p>","PeriodicalId":8017,"journal":{"name":"Annals of surgery","volume":" ","pages":"976-983"},"PeriodicalIF":6.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11543916/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140875659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Training the Surgeon-Scientist: Time (and Money) Well Spent? 培养外科科学家:时间(和金钱)花得值吗?
IF 6.4 1区 医学 Q1 SURGERY Pub Date : 2025-12-01 Epub Date: 2025-06-12 DOI: 10.1097/SLA.0000000000006790
Jeffrey B Matthews
{"title":"Training the Surgeon-Scientist: Time (and Money) Well Spent?","authors":"Jeffrey B Matthews","doi":"10.1097/SLA.0000000000006790","DOIUrl":"10.1097/SLA.0000000000006790","url":null,"abstract":"","PeriodicalId":8017,"journal":{"name":"Annals of surgery","volume":" ","pages":"906-907"},"PeriodicalIF":6.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144273978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Defining Benchmarks for Pelvic Exenteration Surgery: A Multicentre Analysis of Patients With Locally Advanced and Recurrent Rectal Cancers. 确定盆腔开腹手术的基准:对局部晚期和复发性直肠癌患者的多中心分析。
IF 6.4 1区 医学 Q1 SURGERY Pub Date : 2025-12-01 Epub Date: 2024-05-15 DOI: 10.1097/SLA.0000000000006348
Kilian G M Brown, Michael J Solomon, Cherry E Koh, Paul A Sutton, Samuel Aguiar, Tiago S Bezerra, Hamish W Clouston, Ashwin Desouza, Eric J Dozois, Amanda L Ersryd, Frank Frizelle, Jonas A Funder, Julio Garcia-Aguilar, Richard Garfinkle, Tamara Glyn, Alexander Heriot, Yukihide Kanemitsu, Chia Y Kong, Helle Ø Kristensen, Songphol Malakorn, David M Mens, Per J Nilsson, Gabriella J Palmer, Emmanouil Pappou, Martha Quinn, Aaron J Quyn, Chucheep Sahakitrungruang, Avanish Saklani, Arne M Solbakken, Jim P Tiernan, Cornelis Verhoef, Daniel Steffens

Objective: To establish globally applicable benchmark outcomes for pelvic exenteration (PE) in patients with locally advanced primary rectal cancer (LARC) and locally recurrent rectal cancer (LRRC), using outcomes achieved at highly specialised centres.

Background: PE is established as the standard of care for selected patients with LARC and LRRC. There are currently no available benchmarks against which surgical performance in PE can be compared for audit and quality improvement.

Methods: This international multicentre retrospective cohort study included patients undergoing PE for LARC or LRRC at 16 highly experienced centres between 2018 and 2023. Ten outcome benchmarks were established in a lower-risk subgroup. Benchmarks were defined by the 75th percentile of the results achieved at the individual centres.

Results: Seven hundred sixty-three patients underwent PE, of which 464 patients (61%) had LARCs and 299 (39%) had LRRCs. Five hundred forty-four patients (71%) who met predefined lower-risk criteria formed the benchmark cohort. For patients with LARC, the calculated benchmark threshold for major complication rate was ≤44%; Comprehensive Complication Index: ≤30.2; 30-day mortality rate: 0%; 90-day mortality rate: ≤4.3%; R0 resection rate: ≥79%. For patients with LRRC, the calculated benchmark threshold for major complication rate was ≤53%; Comprehensive Complication Index: ≤34.1; 30-day mortality rate: 0%; 90-day mortality rate: ≤6%; R0 resection rate: ≥77%.

Conclusions: The reported benchmarks for PE in patients with LARC and LRRC represent the best available care for this patient group globally and can be used for rigorous assessment of surgical quality and to facilitate quality improvement initiatives at international exenteration centres.

目的:利用高度专业化中心取得的成果,为局部晚期原发性(LARC)和复发性直肠癌(LRRC)患者的盆腔外扩张术(PE)建立全球适用的基准结果:背景数据:PE 已被确定为 LARC 和 LRRC 部分患者的标准治疗方法。背景数据:PE 已被确定为 LARC 和 LRRC 患者的标准治疗方法,但目前还没有可用的基准来比较 PE 的手术效果,以便进行审计和质量改进:这项国际多中心回顾性队列研究纳入了 2018 年至 2023 年期间在 16 个经验丰富的中心接受 LARC 或 LRRC PE 手术的患者。在低风险亚组中建立了十个结果基准。基准由各中心取得的结果的第75百分位数定义:763名患者接受了PE,其中464名患者(61%)接受了LARC,299名患者(39%)接受了LRRC。符合预定义低风险标准的 544 名患者(71%)组成了基准队列。对于 LARC 患者,计算出的主要并发症发生率基准阈值为:≤44%;综合并发症指数 (CCI):≤30.2;30 天死亡率:0%;90 天死亡率:≤30.2:0%;90天死亡率:≤4.3%;R0切除率:≥79%。对于 LRRC 患者,计算得出的主要并发症发生率基准阈值为:≤53%;CCI:≤34.1;30 天死亡率:0%;90 天死亡率:≤4.3%;R0 切除率:≥79%:0%;90 天死亡率:≤6%;R0 切除率:≥77%:所报告的 LARC 和 LRRC 患者 PE 基准代表了全球范围内该患者群体的最佳治疗水平,可用于严格评估手术质量,并促进国际外科医生中心的质量改进计划。
{"title":"Defining Benchmarks for Pelvic Exenteration Surgery: A Multicentre Analysis of Patients With Locally Advanced and Recurrent Rectal Cancers.","authors":"Kilian G M Brown, Michael J Solomon, Cherry E Koh, Paul A Sutton, Samuel Aguiar, Tiago S Bezerra, Hamish W Clouston, Ashwin Desouza, Eric J Dozois, Amanda L Ersryd, Frank Frizelle, Jonas A Funder, Julio Garcia-Aguilar, Richard Garfinkle, Tamara Glyn, Alexander Heriot, Yukihide Kanemitsu, Chia Y Kong, Helle Ø Kristensen, Songphol Malakorn, David M Mens, Per J Nilsson, Gabriella J Palmer, Emmanouil Pappou, Martha Quinn, Aaron J Quyn, Chucheep Sahakitrungruang, Avanish Saklani, Arne M Solbakken, Jim P Tiernan, Cornelis Verhoef, Daniel Steffens","doi":"10.1097/SLA.0000000000006348","DOIUrl":"10.1097/SLA.0000000000006348","url":null,"abstract":"<p><strong>Objective: </strong>To establish globally applicable benchmark outcomes for pelvic exenteration (PE) in patients with locally advanced primary rectal cancer (LARC) and locally recurrent rectal cancer (LRRC), using outcomes achieved at highly specialised centres.</p><p><strong>Background: </strong>PE is established as the standard of care for selected patients with LARC and LRRC. There are currently no available benchmarks against which surgical performance in PE can be compared for audit and quality improvement.</p><p><strong>Methods: </strong>This international multicentre retrospective cohort study included patients undergoing PE for LARC or LRRC at 16 highly experienced centres between 2018 and 2023. Ten outcome benchmarks were established in a lower-risk subgroup. Benchmarks were defined by the 75th percentile of the results achieved at the individual centres.</p><p><strong>Results: </strong>Seven hundred sixty-three patients underwent PE, of which 464 patients (61%) had LARCs and 299 (39%) had LRRCs. Five hundred forty-four patients (71%) who met predefined lower-risk criteria formed the benchmark cohort. For patients with LARC, the calculated benchmark threshold for major complication rate was ≤44%; Comprehensive Complication Index: ≤30.2; 30-day mortality rate: 0%; 90-day mortality rate: ≤4.3%; R0 resection rate: ≥79%. For patients with LRRC, the calculated benchmark threshold for major complication rate was ≤53%; Comprehensive Complication Index: ≤34.1; 30-day mortality rate: 0%; 90-day mortality rate: ≤6%; R0 resection rate: ≥77%.</p><p><strong>Conclusions: </strong>The reported benchmarks for PE in patients with LARC and LRRC represent the best available care for this patient group globally and can be used for rigorous assessment of surgical quality and to facilitate quality improvement initiatives at international exenteration centres.</p>","PeriodicalId":8017,"journal":{"name":"Annals of surgery","volume":" ","pages":"1118-1126"},"PeriodicalIF":6.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140921227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of Laparoscopic Versus Open Distal Pancreatectomy on Recurrence-free Survival in Patients With Left-sided Pancreatic Cancer: A Randomized Controlled Trial. 腹腔镜与开放式远端胰腺切除术对左侧胰腺癌患者无复发生存率的影响:一项随机对照试验。
IF 6.4 1区 医学 Q1 SURGERY Pub Date : 2025-12-01 Epub Date: 2025-02-25 DOI: 10.1097/SLA.0000000000006681
Chen Liu, He Cheng, Min Wang, Yunqiang Cai, Chongyi Jiang, Liang Tang, Guopei Luo, Kaizhou Jin, Shunrong Ji, Wenyan Xu, Si Shi, Xu Wang, Meng Liu, Weihong Zhao, Xiaowu Xu, Jin Xu, Weiding Wu, Wei Wang, Jianhua Liu, Chenghao Shao, Bing Peng, Renyi Qin, Xianjun Yu

Objective: To evaluate the oncological superiority of laparoscopic distal pancreatectomy (LDP) versus open distal pancreatectomy (OPD) in left-sided pancreatic cancer.

Background: The oncological efficacy of LDP in left-sided pancreatic cancer remains controversial.

Methods: We performed a multicenter, open-label, randomized controlled trial of LDP versus OPD in left-sided pancreatic cancer patients. Candidates were recruited from 6 centers in China, and randomly assigned to receive either LDP or ODP. The primary outcome was recurrence-free survival, and the secondary outcomes were overall survival, R0 resection rate, and retrieved lymph node numbers.

Results: Of the 481 eligible pancreatic cancer patients between January 9, 2019 and December 8, 2021, 306 candidates were initially enrolled and randomly assigned at 1:1 to receive either LDP or ODP. The last follow-up was performed on December 15, 2023, and 130 patients in the LDP group and 129 patients in the ODP group were included for per-protocol analysis. Median recurrence-free survival was 15.5 (12.5-18.5) months in the LDP group compared with 15 (9.5-20.5) months in the ODP group ( P = 0.471). The R0 resection rate in 2 groups was 88.5% versus 89.1%, respectively. Median retrieved lymph node numbers in 2 groups were similar [13.5 (10-20) vs 12 (7-17), P = 0.165]. Complications with a Clavien-Dindo score ≥ 3 occurred in 10 of 130 patients in the LDP group, and 11 of 129 patients in the ODP group.

Conclusions: Although LDP did not provide significant oncological benefits for left-sided pancreatic cancer, it was safe, applicable, and appropriate.

目的:本试验的目的是评价腹腔镜胰腺远端切除术与开放式胰腺远端切除术在治疗左侧胰腺癌中的肿瘤学优势。背景:腹腔镜胰腺远端切除术治疗左侧胰腺癌的肿瘤学疗效仍有争议。方法:我们对左侧胰腺癌患者进行了一项多中心、开放标签、随机对照的腹腔镜与开放式远端胰腺切除术试验。候选人从中国的六个中心招募,并随机分配接受LDP或ODP。主要终点是无复发生存期,次要终点是总生存期、R0切除率和淋巴结数量。结果:在2019年1月9日至2021年12月8日期间的481名符合条件的胰腺癌患者中,306名候选人最初被招募,并按1:1的比例随机分配接受LDP或ODP。最后一次随访于2023年12月15日进行,共纳入130例LDP组患者和129例ODP组患者进行方案分析。LDP组中位RFS为15.5(12.5-18.5)个月,而ODP组中位RFS为15(9.5-20.5)个月(P=0.471)。两组R0切除率分别为88.5%和89.1%。两组中位淋巴结数目相近(13.5个[10-20]vs 12个[7-17],P=0.165)。130例LDP组患者中有10例出现Clavien-Dindo评分≥3的并发症,129例ODP组患者中有11例出现并发症。结论:虽然LDP对左侧胰腺癌没有明显的肿瘤学益处,但它是安全适用的。ClinicalTrials.gov NCT03792932。
{"title":"Effect of Laparoscopic Versus Open Distal Pancreatectomy on Recurrence-free Survival in Patients With Left-sided Pancreatic Cancer: A Randomized Controlled Trial.","authors":"Chen Liu, He Cheng, Min Wang, Yunqiang Cai, Chongyi Jiang, Liang Tang, Guopei Luo, Kaizhou Jin, Shunrong Ji, Wenyan Xu, Si Shi, Xu Wang, Meng Liu, Weihong Zhao, Xiaowu Xu, Jin Xu, Weiding Wu, Wei Wang, Jianhua Liu, Chenghao Shao, Bing Peng, Renyi Qin, Xianjun Yu","doi":"10.1097/SLA.0000000000006681","DOIUrl":"10.1097/SLA.0000000000006681","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the oncological superiority of laparoscopic distal pancreatectomy (LDP) versus open distal pancreatectomy (OPD) in left-sided pancreatic cancer.</p><p><strong>Background: </strong>The oncological efficacy of LDP in left-sided pancreatic cancer remains controversial.</p><p><strong>Methods: </strong>We performed a multicenter, open-label, randomized controlled trial of LDP versus OPD in left-sided pancreatic cancer patients. Candidates were recruited from 6 centers in China, and randomly assigned to receive either LDP or ODP. The primary outcome was recurrence-free survival, and the secondary outcomes were overall survival, R0 resection rate, and retrieved lymph node numbers.</p><p><strong>Results: </strong>Of the 481 eligible pancreatic cancer patients between January 9, 2019 and December 8, 2021, 306 candidates were initially enrolled and randomly assigned at 1:1 to receive either LDP or ODP. The last follow-up was performed on December 15, 2023, and 130 patients in the LDP group and 129 patients in the ODP group were included for per-protocol analysis. Median recurrence-free survival was 15.5 (12.5-18.5) months in the LDP group compared with 15 (9.5-20.5) months in the ODP group ( P = 0.471). The R0 resection rate in 2 groups was 88.5% versus 89.1%, respectively. Median retrieved lymph node numbers in 2 groups were similar [13.5 (10-20) vs 12 (7-17), P = 0.165]. Complications with a Clavien-Dindo score ≥ 3 occurred in 10 of 130 patients in the LDP group, and 11 of 129 patients in the ODP group.</p><p><strong>Conclusions: </strong>Although LDP did not provide significant oncological benefits for left-sided pancreatic cancer, it was safe, applicable, and appropriate.</p>","PeriodicalId":8017,"journal":{"name":"Annals of surgery","volume":" ","pages":"930-938"},"PeriodicalIF":6.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143490552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Performance of an Algorithm Grading Surgery-Related Adverse Events According to the Clavien-Dindo Classification. 一种基于Clavien-Dindo分类的手术相关不良事件分级算法的性能。
IF 6.4 1区 医学 Q1 SURGERY Pub Date : 2025-12-01 Epub Date: 2025-01-15 DOI: 10.1097/SLA.0000000000006629
Lisen Båverud Olsson, Dennis Parkan, Annika Sjövall, Pontus Nauclér, Suzanne D van der Werff, Christian Buchli

Objective: To assess the performance of an algorithm for automated grading of surgery-related adverse events (AEs) according to Clavien-Dindo (C-D) classification.

Background: Surgery-related AEs are common, lead to increased patient morbidity, and raise health care costs. Resource-intensive manual chart review is still standard, and, to our knowledge, algorithms using electronic health record (EHR) data to grade AEs according to C-D classification have not been explored.

Methods: The algorithm was developed in a research database containing all EHR data of Karolinska University Hospital Stockholm and returns a C-D grade for each AE within 30 days. This raw score was used to grade the postoperative recovery of 1379 elective colorectal procedures according to C-D classification and Comprehensive Complication Index. Agreement with manual annotation of colorectal surgeon (gold standard) and research nurse (current practice) was assessed in a random sample of 399 procedures.

Results: For the C-D classification, kappa was 0.77 (95% CI: 0.71 to 0.84) for algorithm versus surgeon and 0.74 (95% CI: 0.67 to 0.82) for algorithm versus nurse. The kappa value increased to 0.89 (95% CI: 0.84 to 0.95) after the correction of misclassified annotations by the surgeon. The intraclass correlation for Comprehensive Complication Index between algorithm and surgeon was 0.89 (95% CI: 0.87 to 0.91) after correction and 0.76 (95% CI: 0.71 to 0.80) for algorithm versus nurse.

Conclusions: The performance of the algorithm motivates in our opinion implementation to real-time data under continuous scientific evaluation of the impact on AEs in different types of surgery. In the future, local EHR data could be used to enhance risk prediction with machine learning techniques.

目的:根据Clavien-Dindo (C-D)分类评估手术相关不良事件(ae)自动分级算法的性能。摘要背景资料:手术相关的不良事件很常见,导致患者发病率增加,并增加医疗费用。据我们所知,使用电子健康记录(EHR)数据根据C-D分类对ae进行分级的算法尚未探索。方法:该算法在包含斯德哥尔摩卡罗林斯卡大学医院所有电子病历数据的研究数据库中开发,并在30天内对每个AE返回C-D级。根据C-D分类和综合并发症指数®(CCI),使用该原始评分对1379例选择性结直肠手术的术后恢复进行分级。在399例手术的随机样本中评估结直肠外科医生(金标准)和研究护士(现行实践)的手工注释是否一致。结果:对于C-D分类,算法与外科医生的kappa为0.77 (95%CI 0.71-0.84),算法与护士的kappa为0.74 (95%CI 0.67-0.82)。对外科医生的误分类注释进行校正后,kappa值提高到0.89 (95%CI 0.84 ~ 0.95)。算法与外科医生校正后CCI的类内相关性为0.89 (95%CI 0.87-0.91),算法与护士校正后CCI的类内相关性为0.76 (95%CI 0.71-0.80)。结论:在持续科学评估不同类型手术对ae影响的情况下,我们认为该算法的性能推动了实时数据的实现。在未来,本地电子病历数据可以通过机器学习技术来增强风险预测。
{"title":"Performance of an Algorithm Grading Surgery-Related Adverse Events According to the Clavien-Dindo Classification.","authors":"Lisen Båverud Olsson, Dennis Parkan, Annika Sjövall, Pontus Nauclér, Suzanne D van der Werff, Christian Buchli","doi":"10.1097/SLA.0000000000006629","DOIUrl":"10.1097/SLA.0000000000006629","url":null,"abstract":"<p><strong>Objective: </strong>To assess the performance of an algorithm for automated grading of surgery-related adverse events (AEs) according to Clavien-Dindo (C-D) classification.</p><p><strong>Background: </strong>Surgery-related AEs are common, lead to increased patient morbidity, and raise health care costs. Resource-intensive manual chart review is still standard, and, to our knowledge, algorithms using electronic health record (EHR) data to grade AEs according to C-D classification have not been explored.</p><p><strong>Methods: </strong>The algorithm was developed in a research database containing all EHR data of Karolinska University Hospital Stockholm and returns a C-D grade for each AE within 30 days. This raw score was used to grade the postoperative recovery of 1379 elective colorectal procedures according to C-D classification and Comprehensive Complication Index. Agreement with manual annotation of colorectal surgeon (gold standard) and research nurse (current practice) was assessed in a random sample of 399 procedures.</p><p><strong>Results: </strong>For the C-D classification, kappa was 0.77 (95% CI: 0.71 to 0.84) for algorithm versus surgeon and 0.74 (95% CI: 0.67 to 0.82) for algorithm versus nurse. The kappa value increased to 0.89 (95% CI: 0.84 to 0.95) after the correction of misclassified annotations by the surgeon. The intraclass correlation for Comprehensive Complication Index between algorithm and surgeon was 0.89 (95% CI: 0.87 to 0.91) after correction and 0.76 (95% CI: 0.71 to 0.80) for algorithm versus nurse.</p><p><strong>Conclusions: </strong>The performance of the algorithm motivates in our opinion implementation to real-time data under continuous scientific evaluation of the impact on AEs in different types of surgery. In the future, local EHR data could be used to enhance risk prediction with machine learning techniques.</p>","PeriodicalId":8017,"journal":{"name":"Annals of surgery","volume":" ","pages":"889-896"},"PeriodicalIF":6.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142982546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Characterization of Pancreatic Fistula After Post-pancreatectomy Acute Pancreatitis. 胰腺切除术后急性胰腺炎后胰腺瘘的特征。
IF 6.4 1区 医学 Q1 SURGERY Pub Date : 2025-12-01 Epub Date: 2024-03-19 DOI: 10.1097/SLA.0000000000006277
Haoda Chen, Weishen Wang, Ningzhen Fu, Wentao Xia, Hongzhe Li, Yuchen Ji, Jingyu Zhong, Jiancheng Wang, Xiaxing Deng, Zhiwei Xu, Yuanchi Weng, Baiyong Shen

Objective: This study aimed to investigate the clinical significance and risk factors of postoperative pancreatic fistula (POPF) after post-pancreatectomy acute pancreatitis (PPAP) in patients who underwent pancreaticoduodenectomy (PD).

Background: PPAP has been recognized as a critical factor in the pathophysiology of POPF after PD.

Methods: A total of 817 consecutive patients who underwent elective PD between January 2020 and June 2022 were included. PPAP and POPF were defined in accordance with the International Study Group for Pancreatic Surgery (ISGPS) definitions. Multivariate logistic analyses were performed to investigate the risk factors for POPF. Comparisons between PPAP-associated POPF and non-PPAP-associated POPF were made to further characterize this intriguing complication.

Results: Overall, 159 (19.5%) patients developed POPF after PD, of which 73 (45.9%) occurred following PPAP, and the remaining 86 (54.1%) had non-PPAP-associated POPF. Patients with PPAP-associated POPF experienced significantly higher morbidity than patients without POPF. Multivariate analyses revealed distinct risk factors for each POPF type. For PPAP-associated POPF, independent risk factors included estimated blood loss >200 mL (OR: 1.93), main pancreatic duct ≤3 cm (OR: 2.88), and soft pancreatic texture (OR: 2.01), largely overlapping with fistula risk score elements. On the other hand, non-PPAP-associated POPF was associated with age >65 years (OR: 1.95), male (OR: 2.10), and main pancreatic duct ≤3 cm (OR: 2.57). Notably, among patients with PPAP, the incidence of POPF consistently hovered around 50% regardless of the fistula risk score stratification.

Conclusions: PPAP-associated POPF presents as a distinct pathophysiology in the development of POPF after PD, potentially opening doors for future prevention strategies targeting the early postoperative period.

研究目的本研究旨在探讨胰十二指肠切除术(PD)患者胰腺切除术后急性胰腺炎(PPAP)术后胰瘘(POPF)的临床意义和风险因素:PPAP 已被认为是胰十二指肠切除术后急性胰腺炎病理生理学的一个关键因素:方法:纳入2020年1月至2022年6月期间接受择期PD的817例连续患者。PPAP和POPF根据国际胰腺外科研究小组(ISGPS)的定义进行定义。为研究 POPF 的风险因素,进行了多变量逻辑分析。对与PPAP相关的POPF和非PPAP相关的POPF进行了比较,以进一步确定这一引人关注的并发症的特征:共有 159 例(19.5%)患者在 PD 后出现 POPF,其中 73 例(45.9%)发生在 PPAP 后,其余 86 例(54.1%)为非 PPAP 相关 POPF。PPAP相关POPF患者的发病率明显高于非POPF患者。多变量分析显示,每种 POPF 类型都有不同的风险因素。对于 PPAP 相关 POPF,独立风险因素包括估计失血量 >200 mL(OR 1.93)、MPD ≤3 cm(OR 2.88)和软胰腺质地(OR 2.01),这些因素与 FRS(瘘管风险评分)要素基本重叠。另一方面,非 PPAP 相关的 POPF 与年龄大于 65 岁(OR 1.95)、男性(OR 2.10)和 MPD ≤3 厘米(OR 2.57)相关。值得注意的是,在 PPAP 患者中,无论 FRS 如何分层,POPF 的发生率始终徘徊在 50%左右:结论:与 PPAP 相关的 POPF 在 PD 后 POPF 的发展过程中呈现出独特的病理生理学特征,为未来针对术后早期的预防策略提供了可能。
{"title":"Characterization of Pancreatic Fistula After Post-pancreatectomy Acute Pancreatitis.","authors":"Haoda Chen, Weishen Wang, Ningzhen Fu, Wentao Xia, Hongzhe Li, Yuchen Ji, Jingyu Zhong, Jiancheng Wang, Xiaxing Deng, Zhiwei Xu, Yuanchi Weng, Baiyong Shen","doi":"10.1097/SLA.0000000000006277","DOIUrl":"10.1097/SLA.0000000000006277","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to investigate the clinical significance and risk factors of postoperative pancreatic fistula (POPF) after post-pancreatectomy acute pancreatitis (PPAP) in patients who underwent pancreaticoduodenectomy (PD).</p><p><strong>Background: </strong>PPAP has been recognized as a critical factor in the pathophysiology of POPF after PD.</p><p><strong>Methods: </strong>A total of 817 consecutive patients who underwent elective PD between January 2020 and June 2022 were included. PPAP and POPF were defined in accordance with the International Study Group for Pancreatic Surgery (ISGPS) definitions. Multivariate logistic analyses were performed to investigate the risk factors for POPF. Comparisons between PPAP-associated POPF and non-PPAP-associated POPF were made to further characterize this intriguing complication.</p><p><strong>Results: </strong>Overall, 159 (19.5%) patients developed POPF after PD, of which 73 (45.9%) occurred following PPAP, and the remaining 86 (54.1%) had non-PPAP-associated POPF. Patients with PPAP-associated POPF experienced significantly higher morbidity than patients without POPF. Multivariate analyses revealed distinct risk factors for each POPF type. For PPAP-associated POPF, independent risk factors included estimated blood loss >200 mL (OR: 1.93), main pancreatic duct ≤3 cm (OR: 2.88), and soft pancreatic texture (OR: 2.01), largely overlapping with fistula risk score elements. On the other hand, non-PPAP-associated POPF was associated with age >65 years (OR: 1.95), male (OR: 2.10), and main pancreatic duct ≤3 cm (OR: 2.57). Notably, among patients with PPAP, the incidence of POPF consistently hovered around 50% regardless of the fistula risk score stratification.</p><p><strong>Conclusions: </strong>PPAP-associated POPF presents as a distinct pathophysiology in the development of POPF after PD, potentially opening doors for future prevention strategies targeting the early postoperative period.</p>","PeriodicalId":8017,"journal":{"name":"Annals of surgery","volume":" ","pages":"1045-1051"},"PeriodicalIF":6.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140157396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Infrapopliteal Endovascular Interventions for Claudication Are Associated With Poor Long-term Outcomes in Medicare-matched Registry Patients. 在医疗保险匹配登记患者中,针对跛行的膝下血管内介入治疗与不良的长期疗效有关。
IF 6.4 1区 医学 Q1 SURGERY Pub Date : 2025-12-01 Epub Date: 2024-06-06 DOI: 10.1097/SLA.0000000000006368
Sanuja Bose, Katherine M McDermott, Chen Dun, Jialin Mao, Alex J Solomon, James H Black, Jesse A Columbo, Michael S Conte, Sarah E Deery, Philip P Goodney, Rohan Kalathiya, Corey A Kalbaugh, Jeffrey J Siracuse, Karen Woo, Martin A Makary, Caitlin W Hicks

Objective: To evaluate the association of infrapopliteal peripheral vascular intervention (PVI) with long-term outcomes compared with isolated femoropopliteal PVI for the treatment of claudication.

Background: There are limited data supporting or opposing the use of infrapopliteal PVIs for the treatment of claudication.

Methods: We conducted a retrospective analysis of all patients in the Medicare-matched Vascular Quality Initiative database who underwent an index infrainguinal PVI for claudication from January 2004 to December 2019 using Cox proportional hazards models.

Results: Of 14,261 patients (39.9% females; 85.6% age ≥65 years, 87.7% non-Hispanic White) who underwent an index infrainguinal PVI for claudication, 16.6% (N = 2369) received an infrapopliteal PVI. The median follow-up after index PVI was 3.7 years (interquartile range: 2.1-6.1). Compared with patients who underwent isolated femoropopliteal PVI, patients receiving any infrapopliteal PVI had a higher 3-year cumulative incidence of conversion to chronic limb-threatening ischemia (33.3% vs 23.8%; P < 0.001), repeat PVI (41.0% vs 38.2%; P < 0.01), and amputation (8.1% vs 2.8%; P < 0.001). After risk adjustment, patients undergoing infrapopliteal PVI had a higher risk of conversion to chronic limb-threatening ischemia [adjusted hazard ratio (aHR): 1.39, 95% CI: 1.25-1.53], repeat PVI (aHR: 1.10, 95% CI: 1.01-1.19), and amputation (aHR: 2.18, 95% CI: 1.77-2.67). Findings were consistent after adjusting for competing risk of death, in a 1:1 propensity-matched analysis, and in subgroup analyses stratified by TASC disease, diabetes, and end-stage kidney disease.

Conclusions: Infrapopliteal PVI is associated with worse long-term outcomes than femoropopliteal PVI for claudication. These risks should be discussed with patients.

背景:支持或反对使用髂下外周血管介入术(PVI)治疗跛行的数据有限:我们的目的是评估在治疗跛行时,与孤立的股腘部外周血管介入治疗相比,腘下外周血管介入治疗与长期疗效之间的关系:我们使用 Cox 比例危险模型对 2004 年 1 月至 2019 年 12 月期间与医疗保险匹配的血管质量倡议数据库中所有因跛行而接受指数腹股沟下 PVI 的患者进行了回顾性分析:在14,261名因跛行接受指数腹股沟下PVI手术的患者中(39.9%为女性;85.6%年龄≥65岁,87.7%为非西班牙裔白人),16.6%(N=2,369)接受了髂腹下PVI手术。指数 PVI 术后的中位随访时间为 3.7 年(IQR 2.1-6.1)。与接受孤立股骨头PVI的患者相比,接受任何膝下PVI的患者转为CLTI的3年累计发生率更高(33.3% vs. 23.8%;PConclusions.):与治疗跛行的股骨盆下 PVI 相比,股骨盆下 PVI 的长期疗效更差。应与患者讨论这些风险。
{"title":"Infrapopliteal Endovascular Interventions for Claudication Are Associated With Poor Long-term Outcomes in Medicare-matched Registry Patients.","authors":"Sanuja Bose, Katherine M McDermott, Chen Dun, Jialin Mao, Alex J Solomon, James H Black, Jesse A Columbo, Michael S Conte, Sarah E Deery, Philip P Goodney, Rohan Kalathiya, Corey A Kalbaugh, Jeffrey J Siracuse, Karen Woo, Martin A Makary, Caitlin W Hicks","doi":"10.1097/SLA.0000000000006368","DOIUrl":"10.1097/SLA.0000000000006368","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the association of infrapopliteal peripheral vascular intervention (PVI) with long-term outcomes compared with isolated femoropopliteal PVI for the treatment of claudication.</p><p><strong>Background: </strong>There are limited data supporting or opposing the use of infrapopliteal PVIs for the treatment of claudication.</p><p><strong>Methods: </strong>We conducted a retrospective analysis of all patients in the Medicare-matched Vascular Quality Initiative database who underwent an index infrainguinal PVI for claudication from January 2004 to December 2019 using Cox proportional hazards models.</p><p><strong>Results: </strong>Of 14,261 patients (39.9% females; 85.6% age ≥65 years, 87.7% non-Hispanic White) who underwent an index infrainguinal PVI for claudication, 16.6% (N = 2369) received an infrapopliteal PVI. The median follow-up after index PVI was 3.7 years (interquartile range: 2.1-6.1). Compared with patients who underwent isolated femoropopliteal PVI, patients receiving any infrapopliteal PVI had a higher 3-year cumulative incidence of conversion to chronic limb-threatening ischemia (33.3% vs 23.8%; P < 0.001), repeat PVI (41.0% vs 38.2%; P < 0.01), and amputation (8.1% vs 2.8%; P < 0.001). After risk adjustment, patients undergoing infrapopliteal PVI had a higher risk of conversion to chronic limb-threatening ischemia [adjusted hazard ratio (aHR): 1.39, 95% CI: 1.25-1.53], repeat PVI (aHR: 1.10, 95% CI: 1.01-1.19), and amputation (aHR: 2.18, 95% CI: 1.77-2.67). Findings were consistent after adjusting for competing risk of death, in a 1:1 propensity-matched analysis, and in subgroup analyses stratified by TASC disease, diabetes, and end-stage kidney disease.</p><p><strong>Conclusions: </strong>Infrapopliteal PVI is associated with worse long-term outcomes than femoropopliteal PVI for claudication. These risks should be discussed with patients.</p>","PeriodicalId":8017,"journal":{"name":"Annals of surgery","volume":" ","pages":"1127-1133"},"PeriodicalIF":6.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11725175/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141260699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Worth the Risk? Standardized Screening to Identify Substance Use Among Patients Before Surgery. 值得冒险吗?在手术前对患者进行标准化筛查以识别药物使用情况。
IF 6.4 1区 医学 Q1 SURGERY Pub Date : 2025-12-01 Epub Date: 2024-05-29 DOI: 10.1097/SLA.0000000000006358
Samantha Cooley, Mark C Bicket, Hanan Mohammed, Yenling Lai, Sarah Evilsizer, Chad M Brummett, Jennifer F Waljee

Objective: We sought to compare the identification of unhealthy substance use before surgery using Tobacco, Alcohol, Prescription medication, and other Substance use (TAPS), a standardized 4-item instrument, versus routine clinical documentation in the electronic medical record (EHR).

Background: Over 20% of individuals exhibit unhealthy substance use before elective surgery. Routine EHR documentation is often based on nonstandard questions that may not fully capture the extent of substance use and are subject to bias. In contrast, brief standardized screening could provide a more efficient and systematic approach.

Methods: We conducted a cross-sectional study among adults (≥18 y) at a preoperative clinic from August to September 2021. Positive screens for unhealthy substances by TAPS were compared with data from the EHR. Sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were reported. Receiver operating characteristic curves were used to assess diagnostic ability. Multivariable logistic regression was used to estimate the predictors of positive screens by TAPS.

Results: The cohort included 240 surgical patients. TAPS screening identified significantly more positive screens than EHR documentation (43.3% vs. 14.2%). Patients with unhealthy substance use were younger (50.8 vs. 56.7 y; P =0.003), and TAPS revealed alcohol misuse in 30.8% of cases, contrasting with 0% in clinician documentation ( P <0.001). Of the 104 TAPS-positive patients, 69.2% were missed by EHR documentation. Sensitivity (31%) and accuracy (AUC=0.65) of clinician documentation for any unhealthy substance use were lower compared with TAPS.

Conclusions: Standardized TAPS screening detected preoperative unhealthy substance use more frequently than routine clinician documentation, emphasizing the need for integrating standardized measures into surgical practice to ensure safer perioperative care and outcomes.

目的:我们试图比较使用烟草、酒精、处方药和其他物质使用(TAPS)(一种标准化的 4 个项目的工具)与电子病历(EHR)中常规临床记录对手术前不健康物质使用的识别:超过 20% 的人在选择性手术前会出现不健康的药物使用。常规的电子病历记录通常基于非标准问题,可能无法完全反映药物使用的程度,而且容易产生偏差。相比之下,简短的标准化筛查可以提供更有效、更系统的方法:我们于 2021 年 8 月至 9 月在一家术前诊所对成年人(≥18 岁)进行了一项横断面研究。将 TAPS 对不健康物质的阳性筛查与电子病历的数据进行了比较。报告了敏感性、特异性、阳性预测值、阴性预测值和准确性。接收者工作特征曲线(ROC)用于评估诊断能力。多变量逻辑回归用于估计 TAPS 阳性筛查的预测因素:结果:研究对象包括 240 名手术患者。TAPS筛查出的阳性筛查率明显高于电子病历记录(43.3% 对 14.2%)。使用不健康药物的患者年龄更小(50.8 岁对 56.7 岁;P=0.003),TAPS 筛查发现的酒精滥用病例占 30.8%,而临床医生记录的这一比例为 0%(结论:标准化 TAPS 筛查发现的手术前酒精滥用病例占 30.8%,而临床医生记录的这一比例为 0%:标准化的 TAPS 筛查比常规的临床医生记录更频繁地发现术前使用不健康药物的情况,强调了将标准化措施纳入外科实践的必要性,以确保围手术期护理和结果更安全。
{"title":"Worth the Risk? Standardized Screening to Identify Substance Use Among Patients Before Surgery.","authors":"Samantha Cooley, Mark C Bicket, Hanan Mohammed, Yenling Lai, Sarah Evilsizer, Chad M Brummett, Jennifer F Waljee","doi":"10.1097/SLA.0000000000006358","DOIUrl":"10.1097/SLA.0000000000006358","url":null,"abstract":"<p><strong>Objective: </strong>We sought to compare the identification of unhealthy substance use before surgery using Tobacco, Alcohol, Prescription medication, and other Substance use (TAPS), a standardized 4-item instrument, versus routine clinical documentation in the electronic medical record (EHR).</p><p><strong>Background: </strong>Over 20% of individuals exhibit unhealthy substance use before elective surgery. Routine EHR documentation is often based on nonstandard questions that may not fully capture the extent of substance use and are subject to bias. In contrast, brief standardized screening could provide a more efficient and systematic approach.</p><p><strong>Methods: </strong>We conducted a cross-sectional study among adults (≥18 y) at a preoperative clinic from August to September 2021. Positive screens for unhealthy substances by TAPS were compared with data from the EHR. Sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were reported. Receiver operating characteristic curves were used to assess diagnostic ability. Multivariable logistic regression was used to estimate the predictors of positive screens by TAPS.</p><p><strong>Results: </strong>The cohort included 240 surgical patients. TAPS screening identified significantly more positive screens than EHR documentation (43.3% vs. 14.2%). Patients with unhealthy substance use were younger (50.8 vs. 56.7 y; P =0.003), and TAPS revealed alcohol misuse in 30.8% of cases, contrasting with 0% in clinician documentation ( P <0.001). Of the 104 TAPS-positive patients, 69.2% were missed by EHR documentation. Sensitivity (31%) and accuracy (AUC=0.65) of clinician documentation for any unhealthy substance use were lower compared with TAPS.</p><p><strong>Conclusions: </strong>Standardized TAPS screening detected preoperative unhealthy substance use more frequently than routine clinician documentation, emphasizing the need for integrating standardized measures into surgical practice to ensure safer perioperative care and outcomes.</p>","PeriodicalId":8017,"journal":{"name":"Annals of surgery","volume":" ","pages":"991-997"},"PeriodicalIF":6.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12594147/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141174453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Hidden Battle of Distrust. 隐藏的不信任之战。
IF 6.4 1区 医学 Q1 SURGERY Pub Date : 2025-12-01 Epub Date: 2025-05-13 DOI: 10.1097/SLA.0000000000006752
Toba Bolaji, Selwyn Rogers
{"title":"The Hidden Battle of Distrust.","authors":"Toba Bolaji, Selwyn Rogers","doi":"10.1097/SLA.0000000000006752","DOIUrl":"10.1097/SLA.0000000000006752","url":null,"abstract":"","PeriodicalId":8017,"journal":{"name":"Annals of surgery","volume":" ","pages":"922-923"},"PeriodicalIF":6.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143965080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Annals of surgery
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1